Abstract Thyroid cancer is common, yet the sequence of alterations that promote tumor formation are incompletely understood. Here, we describe a novel model of thyroid carcinoma in zebrafish that reveals temporal changes due to BRAF V600E . Through the use of real-time in vivo imaging, we observe disruption in thyroid follicle structure that occurs early in thyroid development. Combinatorial treatment using BRAF and MEK inhibitors reversed the developmental effects induced by BRAF V600E . Adult zebrafish expressing BRAF V600E in thyrocytes developed invasive carcinoma. We identified a gene expression signature from zebrafish thyroid cancer that is predictive of disease-free survival in patients with papillary thyroid cancer. Gene expression studies nominated TWIST2 as a key effector downstream of BRAF. Using CRISPR/Cas9 to genetically inactivate a TWIST2 orthologue, we suppressed the effects of BRAF V600E and restored thyroid morphology and hormone synthesis. These data suggest that expression of TWIST2 plays a role in an early step of BRAF V600E -mediated transformation.
Introduction
Papillary and follicular thyroid cancers are highly prevalent malignancies arising from transformation of epithelial cells. Mutations in key signaling effectors of the mitogen activated protein kinase (MAPK) pathway, including BRAF and RAS, are found in 70% of thyroid cancers. A recurrent activating mutation in BRAF, BRAF V600E , is found in 45% of papillary thyroid cancers (PTC), the most common histologic subtype (Xing, 2005) . Although patients with PTC may be cured with surgery and radioiodine treatment, mutations in BRAF are associated with an increased risk of disease recurrence . Therefore, it is important to understand the cellular and molecular mechanisms in thyrocytes that lead to malignant transformation by BRAF V600E .
Mutations in BRAF have been linked to several mechanisms of malignant transformation. Expression of BRAF V600E has been demonstrated to increase thyrocyte migration and invasion through induction of an epithelial to mesenchymal transition (EMT) in vitro (Baquero et al., 2013) . Transgenic mouse models demonstrate that expression of BRAF V600E leads to aggressive papillary thyroid carcinomas that progresses to poorly differentiated cancers and demonstrate a loss of sodium iodide symporter expression and a failure to concentrate iodine (Knauf et al., 2005 Chakravarty et al., 2011 ). Yet many human BRAF V600E mutant PTCs are slow growing cancers, that may be clinically stable for years, and identifying these tumors is a key clinical challenge (Haser et al., 2016a (Haser et al., , 2016b . While current animal models largely recapitulate aggressive thyroid cancers, there is a need to identify the molecular characteristics that differentiate indolent thyroid cancer from more aggressive subtypes and understand the molecular mechanisms that are involved in progression.
Understanding the temporal consequences of BRAF V600E expression in thyrocytes and thyroid follicles is a key to deciphering the mechanism of malignant transformation. For this reason, we developed a zebrafish model to visualize the consequences of BRAF V600E expression on thyrocyte follicle structure, hormone synthesis, and organ morphogenesis. Expression of BRAF V600E in zebrafish thyrocytes leads to profound disruption of follicle structure and thyroid hormone production, changes that precede an increase in proliferation. Transgenic zebrafish that express BRAF V600E in thyrocytes develop thyroid carcinomas by one year of age with histopathologic hallmarks of human papillary thyroid cancer. Tumors from zebrafish harbor a gene expression signature that stratifies disease recurrence in patients with papillary thyroid carcinoma. We identify an orthologue of human TWIST2, twist3, as a key mediator of BRAF V600E induced EMT in thyrocytes. Using CRISPR/Cas9 gene editing we demonstrate that twist3 loss of function suppresses the effects of BRAF V600E on follicle morphogenesis and hormone production. These studies provide critical insight into the earliest effects of oncogenic BRAF V600E in thyrocytes.
Results

Characterization of transgenic zebrafish expressing BRAF V600E in thyrocytes
In order to investigate the temporal consequences of oncogenic BRAF expression in thyrocytes, we created stable transgenic lines expressing either human BRAF V600E and a TdTomato reporter gene (tg-BRAF V600E -TOM) or TdTomato alone (tg-TOM), both under control of a thyroid-specific promoter (McMenamin et al., 2014 ) ( Figure 1A ). At five days post-fertilization (dpf) control, tg-TOM larvae formed distinct well-organized thyroid follicles composed of TdTomato+ thyrocytes surrounding colloid containing thyroid hormone, positioned in the ventral aspect of the jaw ( Figure 1B) , as previously reported (Wendl et al., 2002; Opitz et al., 2013) . In contrast, tg-BRAF V600E -TOM larvae exhibited profound defects in thyroid follicle morphogenesis, forming disorganized clusters of thyrocytes ( Figure 1C ). This phenotype was followed by live imaging and was highly penetrant.
To investigate whether expression of BRAF V600E in thyroid follicular cells caused variation in thyroid hormone (T4, thyroxine) production or follicle number, we performed whole mount anti-T4 immunostaining to identify individual T4+ follicles. As expected, at 5 dpf tg-TOM larvae formed an average of five T4+ follicles along the ventral-medial axis ( Figure 1D and F). In contrast, tg-BRAF V600E -TOM larvae displayed a significant decrease in the number and size of T4+ follicles ( Figure 1E-G) . To examine the effects on proliferation in BRAF V600E thyrocytes, we stained tg-BRAF V600E -TOM and tg-TOM with Sytox Green Nucleic Acid Stain and counted the total number thyrocytes at 5 dpf. Total thyrocyte number was comparable between tg-BRAF V600E -TOM and tg-TOM control larvae ( Figure 1 -figure supplement 1A-C). Thyrocyte proliferation was further evaluated by BrdU incorporation into newly synthesized DNA. BrdU-positive TdTomato-positive cell number was not significantly different between tg-BRAF V600E -TOM and tg-TOM control larvae ( Figure 1-figure supplement 1D-F) . Additionally, the total area and volume encompassed by TdTomato positive thyroid cells was comparable between tg-BRAF V600E -TOM and control larvae . These results reveal that expression of BRAF V600E in follicular cells disrupts follicle integrity, resulting in decreased number and size of follicles without altering cell number.
Combined inhibition of BRAF V600E and MEK restores follicular morphology in thyrocytes expressing BRAF
V600E
To investigate whether aberrant thyroid follicle morphogenesis in BRAF V600E larvae could be suppressed by inhibition of MAPK signaling, we treated tg-BRAF V600E -TOM and tg-TOM embryos with either dabrafenib, a specific inhibitor BRAF V600E (Kainthla et al., 2014) or selumetinib (Kim and Patel, 2014) , a MEK inhibitor, or the combination of both inhibitors and observed thyroid structure by live imaging. To limit defects caused by inhibition of MAPK signaling on early development, embryos were treated at doses compatible with normal development (Figure 2A ). Vehicle (DMSO) treated tg-BRAF V600E -TOM larvae exhibited disorganized follicular structure in contrast to tg-TOM larvae at 5 dpf ( Figure 2B ). Treatment with either dabrafenib or selumetinib alone was not sufficient to restore normal thyroid morphogenesis in tg-BRAF V600E -TOM larvae. By contrast, combined treatment with both dabrafenib and selumetinib restored normal thyroid follicular structure ( Figure 2B ), T4 production ( Figure 2C) , and led to a significant increase in the number and size of follicles ( Figure 2D and E). Importantly, inhibition of MAPK signaling in tg-TOM larvae had no overt effects on embryo development or thyroid follicular structure, but was associated with a modest decrease in follicle number, consistent with a proliferative requirement in follicle morphogenesis. control and BRAF V600E transgenic larvae. Gene expression analysis revealed significant, differential gene expression between sorted thyrocytes from tg-TOM and tg-BRAF V600E -TOM larvae ( Figure 3B and Figure 3 -source data 1). Several upregulated genes (wnt11r, her6, axin2 and twist3) in tg-BRAF V600E -TOM were validated by qPCR ( Figure 3-figure supplement 1A) . To identify key pathways affected by BRAF V600E expression in thyrocytes, we performed gene set enrichment analysis (GSEA) (Subramanian et al., 2005) . This analysis revealed TGF-b and EMT as the most highly differentially induced pathways in BRAF V600E expressing thyrocytes ( Figure 
BRAF V600E expression in thyrocytes induces thyroid cancer in adult zebrafish
In order to examine the effects of prolonged BRAF V600E expression, we performed a detailed histopathologic study of cohorts of transgenic tg-BRAF V600E -TOM at 5 and 12 months post-fertilization (mpf). Five mpf tg-BRAF V600E -TOM adult animals are characterized by thyroglobulin-positive masses invading adjacent gills and skeletal muscle, features that are not observed in age-matched wild-type tg-TOM animals ( Figure 4C -D). Consistent with constitutive activation of BRAF V600E , we observed a marked increase in p-ERK in thyroid tissue dissected from tg-BRAF V600E -TOM fish compared to control thyroid tissue from tg-TOM fish ( Figure 4E ). However, at this stage, invasive thyrocytes did not harbor nuclear grooves or other cytologic features diagnostic of human papillary thyroid carcinoma.
We analyzed a second cohort of tg-BRAF V600E -TOM adult animals at 12 mpf and found evidence of progressive disease and histologic and cytological features diagnostic of thyroid carcinoma (Figure 5) , including highly invasive carcinomas with thyrocytes invading skeletal muscle and soft tissue ( Figure 5B ). These features were not observed in control tg-TOM animals ( Figure 5B ). We also observed multiple specific cytologic features of papillary thyroid carcinoma including nuclear grooves, crowded and overlapping nuclei, and elongated nuclei ( Figure 5C ). Other features consistent with aggressive thyroid carcinoma including a desmoplastic stromal reaction (2/14 animals, 14%) were observed ( Figure 5C ). These data reveal that persistent expression of BRAF V600E in thyrocytes leads to invasive carcinoma with hallmarks of human PTC in 9/14 animals (64%) at one year.
Gene expression analysis of zebrafish thyroid carcinoma reveals pathways involved in disease progression and a gene expression signature that is predictive of disease-free survival in human PTC
To identify molecular pathways involved during progression of BRAF V600E -induced thyroid carcinoma, TdTomato-positive thyroid carcinomas were micro-dissected from the ventral jaw at 12 mpf and RNA-seq analysis was performed ( Figure 6A ). Transcriptomic analysis revealed significant, differential gene expression between normal thyroid tissue isolated from tg-TOM zebrafish and carcinomas isolated from tg-BRAF V600E -TOM animals ( Figure 6B and Figure 6 -source data 1). To investigate the signaling pathways altered in zebrafish thyroid carcinomas, we performed GSEA analysis ( Figure 6C ). As observed in thyrocytes isolated from larvae, we found persistent upregulation in TGF-b signaling, EMT, and glycolysis gene signatures from thyroid carcinomas isolated from 12 mpf zebrafish ( Figure 6C , highlighted in red). However, in adult thyroid carcinoma we found that the top upregulated gene expression signatures are linked to proliferation and metabolism (MYC, and mTORC1 gene sets, highlighted in green). These results indicate that prolonged expression of BRAF V600E leads to upregulation of gene expression pathways associated with proliferation and regulation of cellular metabolism. Consistent with some BRAF mouse models of thyroid cancer (Charles et al., 2011) we observed a relatively long latency of tumor development. This led us to hypothesize that thyroid carcinomas arising in zebrafish harbor gene expression changes found in indolent human papillary thyroid cancers. To examine this further, we identified a limited set of genes that are significantly deregulated in zebrafish thyroid carcinomas ( Figure 6D , n = 58 genes highlighted in blue, Figure 6 -source data 2) and we used this as a signature to interrogate a reference cohort of 496 human PTCs annotated with clinical outcomes data (Cancer Genome Atlas Research Network, 2014). We find that the gene signature identified in zebrafish stratifies disease-free survival in human patients and identifies patients at significantly lower risk of relapse ( Figure 6E ). These data imply that thyroid Identification of twist3 as a critical mediator of BRAF V600E in thyrocytes
We performed an in silico screen to identify transcription factors associated with BRAF expression in thyrocytes. Using a reference set of RNAseq data from 496 human PTCs, we performed GSEA iteratively across 1657 transcription factors to identify enrichment with genes induced by BRAF To determine the functional requirements for Twist transcription factors downstream of BRAF V600E in thyrocytes, we performed CRISPR/Cas9 gene editing. We designed and validated an sgRNA targeting twist3 in zebrafish embryos. Microinjection of a twist3 targeted sgRNA in combination with recombinant Cas9 protein leads to specific indels in the twist3 gene at the target locus, a majority of which are predicted to disrupt protein coding ( Figure 7B ). In order to examine thyroid effects, we performed CRISPR/Cas9 gene editing of twist3 in tg-BRAF V600E -TOM larvae. After microinjection of sgRNA targeting twist3, we observed rescue of follicle structure and thyroid hormone production in 57/173 (32.9%) embryos ( Figure 7C-D) . In contrast, non-targeting sgRNA-injected tg-BRAF V600E -TOM embryos exhibit profound defects in follicle structure and thyroid hormone production ( Figure 7C ) as previously described. To determine whether the twist3 gene was edited in thyrocytes, we flow sorted TOM+ thyrocytes from 6dpf larvae ( Figure 7E ) injected with twist3 or nontargeting sgRNAs. We isolated gDNA from TOM+ cells and performed a clonal analysis of twist3 gene editing. We identified a deletion in the twist3 gene in 1/12 clones (8.3%) from TOM+ cells isolated from embryos injected with a twist3 targeting sgRNA, and 0/12 clones isolated from TOM+ cells from embryos injected with a non-targeting sgRNA. These data indicate that genetic disruption of twist3 is sufficient to partially rescue the effects of BRAF V600E on thyroid follicle structure and hormone production.
Discussion
Here, we describe the generation and characterization of a novel model of thyroid cancer. We created a transgenic zebrafish expressing BRAF V600E in fluorescently labeled thyrocytes. By following thyrocytes from the earliest stages of specification, we are able to examine the timeline of oncogenic BRAF V600E in vivo where we observe significant disruption of follicle structure and thyroid hormone production. However, thyrocyte number remains normal in larval development. RNAseq analysis from sorted thyrocytes confirms that genes associated with EMT and TGF-b are transcriptionally activated by BRAF V600E . These data suggest that BRAF V600E activation of downstream signaling pathways converges on a gene expression program that results in loss of epithelial organization without affecting proliferation. Pharmacologic inhibition of BRAF/MEK suppresses the morphologic alterations and restores normal thyroid follicle structure. Prolonged expression of oncogenic BRAF V600E leads to slow growing thyroid carcinoma with nuclear features similar to human PTC and gene expression changes conserved in human PTCs and predictive of improved disease free survival. We have taken advantage of the optical clarity of zebrafish larvae to examine the earliest manifestations of oncogenic BRAF V600E activity in vivo. Expression of BRAF V600E leads to a disruption of follicle structure and thyroid hormone synthesis in zebrafish. Our findings are consistent with prior The following source data is available for figure 6:
Source data 1. studies performed in cell culture using rat thyrocytes that demonstrated increased invasion and expression of markers consistent with EMT after expression of BRAF V600E (Riesco-Eizaguirre et al., 2009) . In a mouse model of PTC expression of BRAF V600E led to the development of poorly differentiated carcinomas associated with activation of EMT . Studies in human thyroid cancer cell lines in vitro also demonstrate that expression of BRAF V600E induces SNAIL, represses E-CADHERIN, and leads to increased invasion (Baquero et al., 2013) . Gene expression studies of human papillary thyroid cancer have identified increased expression of key EMT effectors in the invasive front of tumors (Vasko et al., 2007) . BRAF V600E has been found to physically interact and activate p21-activated kinase 1 (PAK1), a serine/threonine kinase involved in promoting migration in human thyroid cancer cell lines (McCarty et al., 2014) . Our data significantly extend these studies and reveal that epithelial organization and thyroid hormone production is disrupted in vivo after expression of BRAF V600E . In contrast to a transgenic mouse models that develops aggressive poorlydifferentiated thyroid carcinomas, our zebrafish model develops relatively slow growing thyroid cancer similar to the majority of human patients with PTC that grow slowly over many years. This has allowed us to dissect early vs. late effects of BRAF signaling on thyrocytes during malignant transformation. Future studies may take advantage of this latency to test candidate genes identified in cancer genomic studies (Landa et al., 2016) , and examine novel pathways that cooperate with BRAF V600E to accelerate tumor initiation and progression.
We tested the effects of small molecule kinase inhibitors, clinically used for treatment of patients with BRAF V600E mutant tumors, using chemical-genetic approaches in transgenic zebrafish larvae.
We find that treatment with either dabrafenib (a BRAF V600E inhibitor) or selumetinib (a MEK inhibitor)
alone is insufficient to suppress the morphologic phenotypes induced by oncogenic BRAF V600E in zebrafish thyrocytes, but combined therapy with both agents suppresses oncogenic signaling and restores normal morphology. Similarly, in a BRAF-mutant ATC mouse model, the combination of PLX4720, a BRAF inhibitor and PD0325901, a MAPK kinase inhibitor, was more potent in suppressing MAPK activation than either agent alone (McFadden et al., 2014) . Clinical studies with these agents in BRAF V600E -mutant melanomas also confirm that combined therapy has greater anti-tumor efficacy in human patients (Long et al., 2014) . Multiple pathways that mediate resistance to BRAF inhibitors have been characterized in melanoma and colorectal carcinoma (Pritchard and Hayward, 2013) . Our findings lead us to speculate that combined therapy with BRAF and MEK inhibitors may be required for treatment of BRAF V600E mutant thyroid carcinoma. This hypothesis is being tested in an ongoing clinical trial examining BRAF inhibition alone versus the combination of BRAF inhibition and MEK inhibition (ClinicalTrials.gov identifier NCT01723202). Prolonged expression of BRAF V600E leads to an invasive thyroid carcinoma with diagnostic features of human papillary thyroid carcinoma in adult zebrafish. Gene expression studies from tumors isolated from adult animals reveal signatures of proliferation and alterations in mTOR signaling during progression. In a mouse model of thyroid cancer genetic inactivation of TSH receptor attenuated tumor initiation suggesting that TSHR signaling cooperates with oncogenic BRAF (Franco et al., 2011) . We suggest that zebrafish thyroid carcinomas may arise slowly due to a relative euthyroid state that does not provoke elevated TSH levels, as seen in mouse models. Alternatively, it is possible that additional genetic alterations may be required for development of carcinoma. Thyroid cancers in zebrafish exhibit similar histologic features to human papillary thyroid cancer. These are relatively slow growing carcinomas that invade local tissues and exhibit a desmoplastic stromal reaction. Key diagnostic features of PTC, such as nuclear grooves and elongation, are observed, indicating conservation of these phenotypes across broad evolutionary distance. Interestingly tumor formation in zebrafish thyroid occurs on a tp53 wild-type background, in contrast to a zebrafish melanoma model in which tp53 loss of function is required for tumor formation (Patton et al., 2005) . These results confirm the importance of cellular context in modulating tumor initiation, consistent with genetic studies from human patients, which demonstrate BRAF mutations in papillary microcarcinomas (Li et al., 2015) , the earliest pathologic lesions identified. By studying the gene expression changes induced by BRAF V600E , we found enrichment of TGF-b/ EMT signatures and a correlation with TWIST2 expression in human papillary thyroid carcinomas. TWIST proteins are over-expressed in a significant fraction of thyroid cancers (Wang et al., 2013) and knockdown of TWIST1 in thyroid cancer cell lines led to a reduction in proliferation and migration (Salerno et al., 2011) . We find that twist3, an orthologue of TWIST2, is significantly upregulated in thyrocytes upon BRAF V600E expression. Using CRISPR/Cas9 gene editing we find that genetic inactivation of twist3 suppressed the effects of oncogenic BRAF V600E in thyrocyte follicle structure and hormone synthesis. To our knowledge, these are the first in vivo data demonstrating a genetic requirement for TWIST expression downstream of BRAF V600E in a thyroid cancer model.
Materials and methods
Generation of constructs
All vectors were created using Gateway recombination (Life Technologies, Carlsbad, CA). A human BRAF V600E middle entry clone was made by PCR amplification as previously described (Ceol et al., 2011) . pME-BRAF V600E , and pME-TdTomato, were used in LR reactions with pDestTol2pA, p3E-polyA and p5E-tg (containing a 514 bp of zebrafish thyroglobulin promoter fragment, as described (McMenaminetal., 2014) to generate pTol2tg:TdTomato-polyA, pTol2tg:EGFP-polyA, and pTol2tg: hBRAFV600E-polyA.
Generation of zebrafish transgenic line
Twenty-five picograms of pTol2tg:TdTomato-pA and 25 pg mRNA encoding the Tol2 transposase were injected into one-cell stage wild type AB larvae to create Tg(tg:TdTomato-pA) transgenic line. F1 TdTomato-positive animals were raised to adulthood and crossed to wild type fish. To create Tg (tg:BRAF V600E -pA;tg:TdTomato-pA) line, transgenic founders (F 0 ) were generated by co-injecting 25 pg pTol2tg:TdTomato-pA with 25 pg pToltg:BRAF V600E -pA and 25 pg mRNA encoding the Tol2 transposase. Injected larvae were raised to adulthood and crossed to wild type fish for transgenic screening. F 1 animals were raised to adulthood and genotyped for the presence of BRAF via PCR. Identification of transgenic Tg(tg:BRAF V600E -pA;tg:TdTomato-pA) line was performed using PCRbased amplification of BRAF in F2 TdTomato-positive larvae. To simplify nomenclature, we refer to larvae/adult Tg(tg:TdTomato-pA), Tg(tg:BRAF V600E -pA;tg:TdTomato-pA) as tg-TOM, and tg-BRAF V600E -TOM, respectively.
Genotyping
Adult zebrafish were anesthetized with 0.004% MS-222 (Tricaine) (Western Chemical, Ferndale, WA), fin clipped and tissue was incubated in 150 ml of PCR lysis solution containing 20 mg/ml Proteinase K (Qiagen, Hilden, Germany) at 55˚C for 60 min and followed by 45 min at 85˚C. At the end of the incubation, lysates were centrifuged at 3000 rpm for 5 min and 100 ml were transferred to a new tube. One ml was used in a 10 ml PCR reaction using primers listed in Supplementary file 1.
Cell counting
Five-day-old larvae were sacrificed and fixed in 4% PFA ON at 4˚C washed in PBS containing 0.1% Tween 20 (PBST), treated with 50 mg/ml proteinase K (Roche, Basel, Switzerland) for 35 min and incubated with Sytox Green Nucleic Acid stain (1:1000, Thermo Fisher Scientific, Waltham, MA) for 1 hr at RT. Larvae were washed with PBST and post-fixed in 4% PFA for 20 min. After several washes with PBST, larvae were mounted in agarose. Z stacks were acquired on a confocal microscope and green-stained nuclei of TdTomato-positive cells were counted in three-dimensional (3D) image stacks using Imaris software (Bitplane, Concord, MA).
BrdU incorporation
Three-day-old embryos were incubated in E3 fish water containing 10 mM BrdU (Sigma, St Louis, MO) and 15% DMSO for 20 min at 4˚C. Medium was replaced with fresh E3 and embryos were incubated for 2 days at 28˚C. Larvae were fixed in 4% PFA for 2 hr at RT, treated with 50 mg/ml proteinase K (Roche, Basel, Switzerland) for 35 min, post-fixed in 4% PFA for 20 min and incubated in 2N HCl for 1 hr. HCl solution was then removed and larvae were incubated in 0.1M Borate buffer, pH 8.5 for 20 min at RT. After several washes in PBT, larvae were incubated with blocking buffer and anti-BrdU antibody (1:200, Sigma, St Louis, MO) as described in Immunofluorescence.
Inhibitor treatment
Larvae were incubated at 18-somite stage in a 1 mL E3 medium containing 0.5% DMSO in a 24-well plate in the presence of the following inhibitors: 2.5 mM Dabrafenib (Selleckchem, Houston, TX), 10 mM Selumetinib (Selleckchem, Houston, TX) or a combination of the two inhibitors. These were the maximal tolerated doses compatible with normal development.
Imaging
Micrographs of whole larvae and adult fish were acquired with a Zeiss Discovery V8 stereomicroscope (Zeiss, Oberkochen, Germany) equipped with epifluorescence and appropriate filters. Live imaging of fluorescence larvae was acquired with a Zeiss LS510 laser scanning confocal microscope (Zeiss, Oberkochen, Germany). Images were further analyzed for detailed quantitative 3D analysis using Imaris software (BitPlane, Concord, MA). Brightfield images of adult fish were captured using a Canon EOS60D camera (Canon, Tokyo, Japan).
Sample preparation and histopathology
Five (n = 5 and n = 10 tg-TOM and tg-BRAF V600E -TOM, respectively) or 12-month old (n = 5 and n = 14 tg-TOM and tg-BRAF V600E -TOM, respectively) animals were sacrificed and fixed in 4% PFA at 4˚C for 3 days, followed by 3 days of decalcification in EDTA 0.5 M pH 8. After dehydration in 70% ethanol and processing using an automatic tissue processor, samples were embedded in paraffin and 5 mm sections were mounted on slides and stained with H&E for histopathologic examination. H&E-stained slides were reviewed with a board certified human pathologist specializing in the diagnosis of thyroid cancer (TS). The specific histopathologic features were reviewed and validated in comparison with normal thyroid specimens.
RNA extraction
Twelve-month-old animals were sacrificed, and TdTomato-positive thyroid tissue was dissected under a stereomicroscope and placed in 500 mL Trizol (Life Technology, Carlsbad, CA). After homogenization, 100 mL of chloroform was added, and the samples were centrifuged at 12,000 x g for 15 min at 4˚C. After centrifugation, the aqueous phase was transferred to a new tube, 300 ml of 70% ethanol was added and purified using an RNeasy Mini spin column (Qiagen, Hilden, Germany) as described by the manufacturer, including DNAse treatment (Qiagen, Hilden, Germany).
Western blot
Five-month-old animals were sacrificed and TdTomato-positive thyroid tissue was dissected under a stereomicroscope and homogenized in 40 ml RIPA buffer (Pierce, Waltham, MA). Five mg of total extract was resolved by SDS-PAGE, transferred to nitrocellulose and probed with the following antibodies: Phospho-p44/42 (1:1000, Cell Signaling, Danvers, MA), p44/42 (1:1000, Cell Signaling, Danvers, MA), thyroglobulin (1:20000, Dako, Glostrup, Denmark) .
Immunohistochemical analysis
Sections were deparaffinized with xylene and washed with ethanol followed by antigen retrieval using the following conditions: H 2 O 2 at pH 9 at 100˚C for 20 min. All immunostains were performed on the Bond III Autostainer (Leica Biosystem, Wetzlar, Germany) using the Bond Polymer Refine Detection kit (Leica Biosystem, Wetzlar, Germany) using the following conditions: blocking for 10 min, anti-TG antibody 1:2000 (Dako, Glostrup, Denmark), anti-PCNA 1:1000 (Sigma, St. Louis, MO) or anti-P-ERK 1:1000 (Cell Signaling, Danvers, MA) for 15 min. Slides were incubated in post primary AP for 8 min, followed by incubation for 8 min in Polymer AP. Slides were incubated with DAB for 10 min, counter stained with hematoxylin for 5 min and scanned using Aperio slide scanner (Leica, Wetzlar, Germany).
Immunofluorescence
For anti-T4 immunofluorescence, 5-day-old larvae were fixed in 4% PFA overnight at 4˚C. They were then washed in PBS containing 0.1% Tween 20 (PBST), treated with 50 mg/ml proteinase K (Roche) for 35 min and post-fixed in 4% PFA for 20 min. After several washes in PBST, larvae were incubated in blocking buffer (PBST containing 1.0% DMSO, 5% goat serum, and 0.8% Triton X-100) for 2 hr at RT, followed by overnight incubation in with anti-T4 antibody (1:2000, MP Biochemical, Solon, OH). After three washes in PBST containing 1% BSA, larvae were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG secondary antibody for 3 hr at RT (1:500; Invitrogen, Carlsbad, CA). Stained larvae were washed in PBST and embedded in 1% low melt agarose for confocal imaging. For anti-E-Cadherin staining 5-day-old larvae were frozen and embedded in OCT (Sakura Finetek, Torrance, CA). Larvae were sectioned at 10 mM on a cryotome and sections were stained with anti-E-cadherin (1:500, Abcam, Cambridge, MA), followed by anti-mouse Alexa Fluor 488.
Embryo dissociation and fluorescence activated cell sorting
Sixty 5 dpf larvae (in triplicate for each transgenic line, tg-TOM and tg-BRAF V600E -TOM) were sacrificed, de-yolked using calcium-free ringer solution, transferred to a 60 ml culture dish containing 4 ml of protease solution (0.25% trypsin, 1 mM EDTA) and incubated at 28˚C for 30 min. The reaction was stopped with 100 ml 100 mM CaCl 2 and 500 ml FBS. Cells were centrifuged for 3 min at 3000 rpm and resuspended in 5 ml of suspension medium (Colorless Leibovitz L-15, 0.8 mM CaCl 2 , penicillin/streptomycin and 1% FBS), centrifuged for 3 min at 3000 rpm, resuspended in 5 ml suspension medium and homogenized with a 10 ml pipette. Twenty U/ml of RNAse inhibitor (Life Technologies, Carlsbad, CA) was added, and the cell suspension passed through a cell strainer tube (BD Bioscience, San Jose, CA). TdTomato-positive cells were sorted using BD FACS Vantage SE with DiVa upgrade cell sorter (Becton, Dickinson and Co., San Jose, CA). For excitation of TdTomato fluorescent protein, 514 nm wavelength of Ar-Kr-ion laser with 200 mW power was used and fluorescence was detected in logarithmic mode via a BP575/26 nm optical filter. TdTomato-positive and negative cells were collected in 250 ml RLT buffer (Qiagen, Hilden, Germany) and nucleic acids were extracted. RNA extraction was performed using an RNeasy Micro Kit (Qiagen, Hilden, Germany) and subjected to DNAse treatment (Qiagen, Hilden, Germany). DNA extraction for clonal analysis of CRISPR/Cas9 activity was performed with an AllPrep DNA/RNA Kit (Qiagen, Hilden, Germany). The quality and the concentration of nucleic acids were assessed using a Bioanalyzer (Agilent, Santa Clara, CA). The RNA samples used in the study had a RIN between 7.4 and 9.4.
Amplification-library preparation and RNA-seq
One ng of RNA from three biological replicates of sorted cells for each transgenic line tg-TOM and tg-BRAF V600E -TOM was used to prepare amplified ds cDNA using Ovation RNA-Seq System V2 (Nugen, San Carlos, CA). Amplified ds cDNA was purified using QIAquick PCR purification kit (Qiagen, Hilden, Germany) and 200 ng of amplified cDNA was fragmented in a final volume of 50 ml using S220 Focused-ultrasonicator (Covaris, Woburn, MA), to obtain 150 bp DNA fragment size (peak incident power: 175W, duty factor: 10%, cycles per burst: 200, time: 280s). Fragmented DNA samples were used to prepare the library using TruSeq RNA sample preparation kit v2 (Illumina, San Diego, CA). For qPCR validation cDNA was diluted 1:7 and 2 ml were used in a 10 ml reaction using the PerfeCTa SYBR Green FastMix (Quanta Biosciences, Gaithersburg, MD). Gapdh was used as a control gene for normalization. Relative gene expression among samples was determined using the deltaC t method (2 -DDC t ). Results are expressed as the mean ± SEM in relative expression. For the library preparation of RNA derived from adult animals, RNA was extracted from dissected thyroid tissues as described and 100 ng from three tg-TOM and five tg-BRAF V600E -TOM biological replicates was used to prepare the library using TruSeq RNA sample preparation kit v2 (Invitrogen, San Diego CA). After validation using an Agilent DNA 1000 LabChip (Agilent, Santa Clara, CA), samples were submitted for RNA-seq.
CRISPR/Cas9 experiments
Gene editing of twist3 was performed by microinjection of 500 pg recombinant S. pyogenes Cas9 (PNA Bio, Thousand Oaks, CA) complexed with 1 mg synthetic sgRNA (ALT-R, Integrated DNA Technologies, Coralville IA). Ribonucleotide-protein complex formation was performed in vitro as described (Zuris et al., 2015) . DNA was extracted from single injected embryos at 24hpf for analysis of indels. The targeted locus in twist3 was PCR amplified using primers listed in Supplementary file 1 and subject to TA cloning in pcr2.1 (Invitrogen). Plasmid DNA was isolated from individual clones and Sanger sequencing was performed. CRISPR/Cas9 gene editing was analyzed using CrispRVariants (Lindsay, 2016) . A T7 Endonuclease I (T7EI) assay was performed using 8 ml of PCR product in 20 ml final reaction containing 2U of T7EI (NEB, Ipswich, MA) for 1 hr at 37˚C. Products were analyzed on a 1% agarose gel.
Bioinformatic analyses
Paired end reads were aligned using Star v2.3 (Dobin et al., 2013) to the zebrafish genome (GRCz10) using the Ensembl transcriptome (Howe et al., 2013) . Analysis of differential gene expression was performed using DESeq2 (Love et al., 2014) . To identify differentially regulated genes between samples, we selected genes with log2 fold change greater than 1.2 or less than À1.2 and an adjusted p-value<0.05. Orthology to human genes was determined using Ensembl (Collins et al., 2012) and supplemented by performing BLAST (Altschul et al., 1990) . GSEA (Subramanian et al., 2005) was performed on RNAseq data using normalized counts and queried against the Hallmark in Cancer signatures from the MSigDB (http://www.broadinstitute.org/gsea/msigdb/index.jsp). Signatures represented in the results are the top 10, FDR < 25%, nominal p-value<5%. For the analysis of disease-free survival in human patients with PTC, we used clinical data from the TCGA PTC cohort (Cancer Genome Atlas Research Network, 2014) . We utilized the adult BRAF V600E signature (n = 58 genes, Figure 6D and Figure 6 -source data 2) to rank genes in the TCGA PTC samples using normalized RNAseq gene expression with a minimum rank method to resolve ties. We calculated the mean rank for the set of signature genes for each subject to estimate the overall regulation of the signature with respect to overall gene expression. We stratified subjects by median rank of the signature and performed a Kaplan-Meier survival analysis using disease free survival as the primary outcome. For the in silico screen to identify transcription factors associated with BRAF V600E gene expression signatures, we utilized normalized gene expression from 496 TCGA PTC samples described (Cancer Genome Atlas Research Network, 2014) . We performed iterative GSEA against all transcription factors to identify enrichment with a BRAF V600E signature identified in larval thyrocytes ( Figure 7 -source data 1).
Zebrafish husbandry
Zebrafish were bred and reared according to established guidelines (Westerfield, 2007) . All studies were performed in compliance with a protocol approved by our Institutional Animal Care and Use Committee (IACUC).
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